TribLIVE

| News


 
Larger text Larger text Smaller text Smaller text | Order Photo Reprints

Treatment devised at Pitt could ease breathing woes

Sunday, March 31, 2013, 12:59 p.m.
 

A new molecule developed in Pittsburgh eases inflammation in rodent cases of pneumonia, a discovery that could help people with respiratory infections, according to research released on Sunday.

A refined version of the treatment eventually “might be useful in improving outcomes” for pneumonia patients, said Dr. Rama Mallampalli, a vice chairman for research in the University of Pittsburgh School of Medicine. He said clinical trials for people could materialize within a few years.

The Department of Veterans Affairs and the National Institutes of Health supported the research, conducted during the past three to four years at Pitt and the VA Pittsburgh Healthcare System.

Mallampalli is the senior author in a paper about the findings, published this week in the journal Nature Immunology.

He said researchers are looking at whether other treatments could have a similar effect on ailments such as arthritis, asthma and colitis, all of which involve inflammation.

 

 

 
 


Show commenting policy

Most-Read Allegheny

  1. Reading Harry Potter provides clues to brain activity, CMU researchers say
  2. Girl, 12, rescues 4-year-old sister from burning house in Homestead
  3. Suspect in Route 28 death has long history of ignoring vehicle registration, license laws, records show
  4. La Roche College to accept up to 90 credits from community college students
  5. U.S. Steel Tower tenants stand to benefit from company’s relocation
  6. Lower gas prices entice motorists to drive long distances for Thanksgiving
  7. Alcoa judgment helps U.S. Attorney’s Office collect 5 times its budget
  8. Brentwood police chief to get nearly $200K as part of settlement agreement with borough
  9. Judges with Pittsburgh ties enter race for Pa. Supreme Court
  10. Newsmaker: Sister Rita Yeasted
  11. Surgery for man shot by Pittsburgh officer on hold amid legal limbo
Subscribe today! Click here for our subscription offers.